 |
|
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
Basic Trial Information
Trial Description
Summary
Further Trial Information
Eligibility Criteria
Trial Contact Information
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention
|
|
|
|
Active
|
|
|
|
45 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
10723
H6Q-MC-S009, NCT00414960
|
|
|
Trial Description
Summary To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups. Further Study Information x Eligibility Criteria Inclusion Criteria: - Sputum atypia participants with normal sputum cytology will be removed from the study)
- Metaplasia or dysplasia on at least one bronchoscopy specimen
- History of cigarette smoking >30 Pack Years
- Quit smoking >1 year prior to study entry
- Able to undergo bronchoscopy and helical CT scanning of the chest
Exclusion Criteria: - Blood clotting abnormalities
- Current smoking within the past 1 year
- Unwillingness to abstain from smoking while enrolled in the clinical trial or are unwillingness to avoid significant second hand smoke exposure
- Evidence for lung cancer or carcinoma in situ
- Active cardiovascular disease
- Current illicit drug or alcohol abuse
Trial Contact Information
Trial Lead Organizations/Sponsors Eli Lilly and Company | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | | Study Director |
| There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or | | Ph: 1-317-615-4559 |
Trial Sites
|
|
|
|
| U.S.A. |
|
| Florida |
|
| |
Tampa |
|
| | | | | | | | | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. |
| | | Eli Lilly | |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00414960
Information obtained from ClinicalTrials.gov on November 18, 2008 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
|
